Facebook
X
LinkedIn
ForwardOptimizing the Use and Safety of ADCs in Metastatic Breast Cancer: Indications, Toxicity Profiles, and Proactive Management
As part of this performance and quality improvement initiative, Reshma L. Mahtani, D.O. reviews the latest clinical evidence, guideline recommendations, and emerging strategies to support the coordinated care of patients receiving antibody-drug conjugates (ADCs). Through expert-led presentations and case-based discussions, participants will explore approaches to optimizing ADC utilization across the continuum of care.
Healthcare professionals will gain practical strategies to improve interdisciplinary collaboration, recognize and manage ADC-related adverse events, and support timely interventions that enhance patient safety and treatment outcomes. This activity is designed to equip clinicians with actionable knowledge that can be applied directly in practice to deliver high-quality, patient-centered care for individuals receiving—or being considered for—ADC therapy.
Commercial Supporter
Baptist Health gratefully acknowledges the educational grants provided by Daiichi Sankyo, Inc. and AstraZeneca.
Target Audience
Breast Medical Oncologists, Radiation Oncologists, Emergency Medicine Physicians, Infusion Nurses, Nurse Navigators, Advanced Practice Registered Nurses, Pharmacists, Pharmacy Technicians, Physician Assistants/Physician Associates, Pulmonologists, Radiologists, Schedulers, Medical Assistants, Patient Care Facilitators, and all personnel involved in the care of the breast cancer patient.
Learning Objectives
Upon completion of this conference, participants should be better able to:
- Discuss indications of the different ADCs in metastatic breast cancer
- Differentiate the toxicity profiles of datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and trastuzumab deruxtecan (T-DXd) (fatigue, nausea, diarrhea, stomatitis, neutropenia).
- Discuss evidence-based, proactive strategies to prevent and manage ADC-related adverse events, including antiemetic protocols, diarrhea management algorithms, growth factor use, oral care for stomatitis, and dose-modification approaches.
- Discuss clinical and radiographic signs of ADC-associated ILD/pneumonitis and management.
Reshma L. Mahtani, D.O.
Chief of Breast Medical Oncology
Miami Cancer Institute
Baptist Health South Florida
Member, Memorial Sloan Kettering Cancer Alliance
Reshma Mahtani, D.O., faculty of this educational activity, is a consultant for Agendia, Arvinas, AstraZeneca, Bicycle Therapeutics, Daiichi Sankyo, Genentech, Gilead, Hologic, Lilly, Novartis, Pfizer, Puma, and Stemline, and indicated that the presentation or discussion will include off-label or unapproved product usage.
All financial relationships have been mitigated.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have relevant financial relationships to disclose with ineligible companies*
*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Artificial Intelligence (AI) Use Disclosure
For this activity, AI was used to assist in developing and refining assessment questions and learner feedback based on medical writer-authored content, and to help align assessments with competency-level outcome measures consistent with ACCME standards. All AI-assisted content received subject matter expert review, validation, and approval before use.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 General certificate of attendance
- 1.50 Nurse Practitioners
- 1.50 Florida Board of Nursing
- 1.50 Florida Board of Pharmacy
Your participation information will be shared with specialty boards through the ACCME's PARS reporting system. Successful completion of a course examination is required. Submissions are recorded in approximately 48 hours. You will receive an email when your credits have been processed.
Required Hardware/Software
PC/Mac Users
This site is supported on the most recent stable releases of the following browsers:
Google Chrome
Microsoft Edge
Safari
Mozilla Firefox
Mobile Users
This site is supported on the following mobile devices:
- Apple iOS mobile devices running iOS 10 or later
- Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
If you are experiencing technical difficulties or have received an error message, please send an email to [email protected] and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.